Clinical burden and health-related quality of life in Chinese patients with mucopolysaccharidosis type Ⅱ under 16 yearsOA
This study assessed the health‑related quality of life(HRQoL)of Chinese patients with mucopolysaccharidosis type Ⅱ(MPS Ⅱ)and explored key factors associated with HRQoL.A cross‑sectional survey was conducted in February 2023 through the China Rare Disease Alliance Cloud Service Platform,in which patients with MPS Ⅱ and their family members completed an online questionnaire collecting information on Pediatric Quality of Life Inventory(PedsQL)Version 4.0 scores,sociodemographic characteristics,and clinical features.Descriptive statistics were used to summarize patient characteristics and HRQoL levels,and multiple linear and logistic regression analyses were performed to identify factors influencing HRQoL.Data were obtained from 129 individuals across 22 regions in China,the majority of whom were boys(98%),with a mean age of 8.7 years.Initial symptoms appeared at approximately 2.5 years of age,yet diagnosis was often delayed by more than one year,and over half of the children(57%)had previously received an incorrect diagnosis.On average,nearly ten body systems were affected.Overall HRQoL was low,with a mean score of 30.08(standard deviation(SD)=19.51).Domain‑specific scores were 30.98 for daily activities,43.18 for emotional well‑being,24.73 for social functioning,and 20.89 for school participation,indicating substantial difficulties in performing routine tasks.Multiple linear regression(adjusted R²=0.381)showed that HRQoL significantly declined with increasing age(β=−2.000,P=0.003)and the presence of neurological or cognitive impairments(β=−12.798,P<0.001),whereas school attendance was a strong positive predictor of higher HRQoL(β=16.330,P<0.001).Overall,Chinese patients with MPS Ⅱ demonstrated markedly reduced HRQoL,particularly in cognitive and daily functioning domains,underscoring the need for improved clinical management and supportive strategies to enhance their well‑being.
Zixuan Lyu;Min Li;Yaqun Wang;Pei Wang;Shengnan Duan;Huaxin Yu;Kexin Li;Jun Hu;Ni Yuan
School of Public Health,Dalian Medical University,Dalian,Liaoning,116044,China Innovative Drug Policy and medical Insurance Research Center,Dalian Medical University,Dalian,Liaoning,116044,China Dong Fureng Institute of Economic and Social Development,Wuhan University,Wuhan,430072,ChinaSchool of Public Health,Dalian Medical University,Dalian,Liaoning,116044,China Innovative Drug Policy and medical Insurance Research Center,Dalian Medical University,Dalian,Liaoning,116044,China School of Public Health,Jiamusi University,Jiamusi,Heilongjiang,154007,ChinaSchool of Public Health,Dalian Medical University,Dalian,Liaoning,116044,China Innovative Drug Policy and medical Insurance Research Center,Dalian Medical University,Dalian,Liaoning,116044,China Dong Fureng Institute of Economic and Social Development,Wuhan University,Wuhan,430072,ChinaSchool of Public Health,Fudan University,Shanghai,200433,ChinaSchool of Public Health,Dalian Medical University,Dalian,Liaoning,116044,China Innovative Drug Policy and medical Insurance Research Center,Dalian Medical University,Dalian,Liaoning,116044,China School of Public Administration,Dongbei University of Finance&Economics,Dalian,Liaoning,116025,ChinaDisease Control and Prevention Center of Jinpu New Area(Health Supervision Institute),Dalian,Liaoning,116600,ChinaChina Alliance for Rare Disease,Beijing,100020,ChinaShanghai Center for Adverse Drug Reaction and Medical Device Monitoring,Shanghai,200040,ChinaSchool of Public Health,Dalian Medical University,Dalian,Liaoning,116044,China Innovative Drug Policy and medical Insurance Research Center,Dalian Medical University,Dalian,Liaoning,116044,China
医药卫生
MucopolysaccharidosesⅡHRQoLPedsQL 4.0Influencing factorsChina
《Pharmacoeconomics and Policy》 2026 (1)
P.38-45,8
评论